SNORD72: A Small Nucleolar RNA in Focus (G619564)

Target Name: SNORD72

NCBI ID: G619564

SNORD72

Other Name(s): small nucleolar RNA, C/D box 72 | Small nucleolar RNA, C/D box 72 | HBII-240

SNORD72: A Small Nucleolar RNA in Focus

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play critical roles in various cellular processes, including DNA replication, gene expression, and translation of RNA into proteins. One of the key snRNAs is called SNORD72, which is a 24.8 kilobase (kb) RNA molecule. It is one of the smaller snRNAs and is located in the 5' end of the X chromosome in humans.

SNORD72 is a well- conserved RNA molecule that is highly conserved in various species, including humans. It is composed of 1,212 amino acids and has a calculated molecular mass of 19.9 kDa. The SNORD72 protein is a key regulator of gene expression and has been involved in various cellular processes.

SNORD72 functions as a binding protein

One of the functions of SNORD72 is as a binding protein. It has been shown to interact with various protein partners, including transcription factors, activators, and repressors. These interactions play a crucial role in the regulation of gene expression and are a key feature of the RNA polymerase complex.

SNORD72 has been shown to interact with the transcription factor, p53. p53 is a well-known tumor suppressor protein that plays a critical role in the regulation of cellular processes, including DNA replication, apoptosis, and cell cycle control. Interactions between SNORD72 and p53 have been shown to regulate the expression of target genes and are a potential therapeutic target for various diseases.

SNORD72 has also been shown to interact with the transcription factor, AP1. AP1 is a transcription factor that is involved in the regulation of cellular processes, including cell growth, differentiation, and DNA replication. Interactions between SNORD72 and AP1 have been shown to regulate the expression of target genes and are also a potential therapeutic target for various diseases.

SNORD72 may be a drug target

SNORD72 is a potential drug target due to its involvement in various cellular processes and its role as a binding protein. SNORD72 has been shown to interact with various protein partners and its function as a binding protein may make it an attractive target for small molecule inhibitors.

In addition, SNORD72 is also known to be a key regulator of gene expression and its dysfunction in various diseases, such as cancer, may be attributed to the regulation of gene expression. Therefore, targeting SNORD72 with small molecules or other therapeutic approaches may be a promising strategy for the treatment of various diseases.

Conclusion

SNORD72 is a small nucleolar RNA that plays critical roles in various cellular processes, including DNA replication, gene expression, and translation of RNA into proteins. It is a well-conserved RNA molecule that is highly conserved in various species, including humans. SNORD72 is also shown to interact with various protein partners, including transcription factors, activators, and repressors. Its function as a binding protein and its involvement in the regulation of gene expression make it a potential drug target for various diseases. Further research is needed to fully understand the role of SNORD72 in cellular processes and its potential as a therapeutic target.

Protein Name: Small Nucleolar RNA, C/D Box 72

The "SNORD72 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD72 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets